ArticleLancet regional health. Americas2026
Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure is associated with high morbidity, mortality, and substantial resource use. Dapagliflozin improves outcomes in heart failure, but local economic evidence for Argentina is limited. We conducted a cost-utility analysis of dapagliflozin added to standard therapy for chronic heart failure in Argentina. Methods: We conducted a cost-utility analysis from the Argentine public health system perspective using two trial-based Markov models (DAPA-HF and DELIVER populations), monthly cycles, lifetime horizon, and 3% annual discounting for costs and outcomes. Inputs were derived from published trial data and Argentine sources where available. We estimated costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), and performed deterministic and probabilistic sensitivity analyses. Findings: In the DAPA-HF model, dapagliflozin increased QALYs by 0.76 with an incremental cost of US$5069, yielding an ICER of US$6672 per QALY. In the DELIVER model, dapagliflozin increased QALYs by 0.44 with an incremental cost of US$4542, yielding an ICER of US$10,371 per QALY. At a willingness-to-pay threshold of 1 gross domestic product (GDP) per capita, the probability of cost-effectiveness was 97% (DAPA-HF) and 73% (DELIVER). Interpretation: Dapagliflozin added to standard therapy is likely to be cost-effective in Argentina, with greater robustness in heart failure with reduced ejection fraction. In preserved or mildly reduced ejection fraction, cost-effectiveness is compatible with a 1 GDP per capita threshold but more sensitive to key assumptions; price negotiation could improve value for money. Funding: None.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.